US 12,130,293 B2
Clinical diagnosis of non-alcoholic fatty liver disease using a panel of human blood protein biomarkers
Bevin Gangadharan, Oxfordshire (GB); Abhinav Kumar, Reading (GB); Raymond A. Dwek, Oxfordshire (GB); Nicole Zitzmann, Oxfordshire (GB); Mark Thursz, Berkhamstead (GB); and Jeremy Francis Lars Cobbold, Witney (GB)
Assigned to SHOX SCIENCE LIMITED, Kowloon (HK)
Filed by ShOx Science Limited, Hong Kong (CN)
Filed on May 17, 2022, as Appl. No. 17/746,341.
Application 17/746,341 is a continuation of application No. 16/326,737, granted, now 11,366,124, previously published as PCT/GB2017/052486, filed on Aug. 23, 2017.
Claims priority of application No. 1614455 (GB), filed on Aug. 24, 2016.
Prior Publication US 2023/0117596 A1, Apr. 20, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/68 (2006.01)
CPC G01N 33/6893 (2013.01) [G01N 2333/775 (2013.01); G01N 2333/811 (2013.01); G01N 2800/085 (2013.01); G01N 2800/56 (2013.01)] 12 Claims
 
1. A method of treating non-alcoholic fatty liver, the method comprising:
diagnosing non-alcoholic fatty liver in an individual, by a method comprising diagnosing, prognosing or monitoring or staging progression of non-alcoholic fatty liver in the individual, the method comprising:
detecting and quantifying thrombospondin-1 in a biological sample obtained from the individual;
comparing the level of thrombospondin-1 in the biological sample obtained from the individual to the level of thrombospondin-1 in a control group of healthy individuals and determining whether the level of thrombospondin-1 in the biological sample obtained from the individual is indicative of progression of non-alcoholic fatty liver, wherein an increasing level of thrombospondin-1, as compared with the control group, indicates increasing severity of non-alcoholic fatty liver in the individual,
and thereby diagnosing, prognosing or monitoring or staging the progression of non-alcoholic fatty liver in the individual; and wherein the method further comprises:
administering an agent or carrying out a regimen to reduce or prevent the development or progression of non-alcoholic fatty liver or effective to treat non-alcoholic fatty liver to the individual.